Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 232

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 232
---
. The Board will meet on a regular basis and additionally as required.

<div align='center'>135</div>

In accordance with the terms of the Company’s amended certificate of incorporation and the amended bylaws, the Board is divided into three classes, Class I, Class II and Class III, with members of each class serving staggered three-year terms. The members of the classes are divided as follows:

| ● | the Class I directors are Susan Shiff and Michael Wyzga, and their terms will expire at the annual meeting of stockholders to be held in 2028; |

| ● | the Class II directors are Imran Alibhai, Cynthia Smith and Sujal Shah, and their terms will expire at the annual meeting of stockholders to be held in 2026; and |

| ● | the Class III director is Wallace Hall, and his terms will expire at the annual meeting of stockholders to be held in 2027. |

In accordance with the terms of the Merger Agreement, our board of directors consists of one member designated by Cara, who is Susan Shiff, Ph.D., and five members designated by Legacy Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Imran Alibhai, Ph.D., and Cynthia Smith. Director Independence Under the Nasdaq Listing Rules, a majority of the members of the board of directors must qualify as “independent,” as affirmatively determined by the board of directors. Under the Nasdaq Listing Rules, a director will only qualify as an “independent director” if, in the opinion of that company’s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The Company’s board of directors has determined that each of its directors other than Dr. Alibhai qualify as “independent directors” as defined by the Nasdaq Listing Rules. Committees of the Board The Board has three standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee. Each committee operates pursuant to a charter, which is available at www.ir.tvarditherapeutics.com. The Board may establish other committees from time to time. Audit Committee The audit committee is responsible for the following activities, among other things:

| ● | evaluating the performance of and assessing the qualifications of the independent auditors; |

| ● | determining and approving the engagement of the independent auditors; |

| ● | determining whether to retain or terminate the engagement